SynthesisMedicine2017
The influence of different growth hormone addition protocols to poor ovarian responders on clinical outcomes in controlled ovary stimulation cycles: A systematic review and meta-analysis.
Synthesis in Medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05281341 (Effect of Growth Hormone Administration With Controlled Ovarian Stimulation in Expected Poor Responders POSEIDON Group 3 and 4 Undergoing ICSI Using Antagonist Protocol), which is not on this map. Cited by 49 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Growth Hormone Administration With Controlled Ovarian Stimulation in Expected Poor Responders POSEIDON Group 3 and 4 Undergoing ICSI Using Antagonist Protocol
Who cites it
49 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Growth hormone improves the pregnancy outcomes in poor ovarian responders undergoing in vitro fertilization: an umbrella review.Journal of assisted reproduction and genetics · 2025Pooled it
- Meta-analysis of GnRH-antagonists versus GnRH-agonists in poor responder protocols.Archives of gynecology and obstetrics · 2021Pooled it
- The effect of growth hormone supplementation in poor ovarian responders undergoing IVF or ICSI: a meta-analysis of randomized controlled trials.Reproductive biology and endocrinology : RB&E · 2020Pooled it
- Improvement of Pregnancy Rate and Live Birth Rate in Poor Ovarian Responders by Intraovarian Administration of Autologous Menstrual Blood Derived- Mesenchymal Stromal Cells: Phase I/II Clinical Trial.Stem cell reviews and reports · 2020Trial
- Growth Hormone (GH) Improvement of Ovarian Responses and Pregnancy Outcome in Poor Ovarian Responders: A Randomized Study.Asian Pacific journal of cancer prevention : APJCP · 2019Trial
- [Growth hormone and fertility: molecular mechanisms and experience of adjuvant therapy in reproductology].Problemy endokrinologii · 2026Review
- Comparative efficacy of different growth hormone supplementation protocols in improving clinical outcomes in women with poor ovarian response undergoing assisted reproductive therapy: a network meta-analysis.Scientific reports · 2024Article
- Growth hormone treatment improves the development of follicles and oocytes in prepubertal lambs.Journal of ovarian research · 2023Article
- Growth hormone reduces aneuploidy and improves oocytes quality by JAK2-MAPK3/1 pathway in aged mice.Journal of translational medicine · 2023Article
- Hyperbaric Oxygen Treatment Ameliorates the Decline in Oocyte Quality and Improves the Fertility of Aged Female Mice.Reproductive sciences (Thousand Oaks, Calif.) · 2023Article
- The effect of growth hormone on the metabolome of follicular fluid in patients with diminished ovarian reserve.Reproductive biology and endocrinology : RB&E · 2023Observational
- The effect of growth hormone on ovarian function recovery in a mouse model of ovarian insufficiency.Frontiers in endocrinology · 2023Article
- The Clinical Application of Growth Hormone and Its Biological and Molecular Mechanisms in Assisted Reproduction.International journal of molecular sciences · 2022Review
- Researching the Phenomenon of Poor Ovarian Responders and Management Strategies in IVF: A Narrative Review.Acta medica academica · 2022Review
- Comparison of two ovarian stimulation protocols among women with poor response: A randomized clinical trial.European journal of translational myology · 2022Article
- Effects of Adjuvant Growth Hormone Therapy on Poor Ovarian Responders in Assisted Reproductive Technology.Maedica · 2022Article
- Importance of IGF-I levels in IVF: potential relevance for growth hormone (GH) supplementation.Journal of assisted reproduction and genetics · 2022Article
- Growth hormone in fertility and infertility: Mechanisms of action and clinical applications.Frontiers in endocrinology · 2022Review
- The role of growth hormone in assisted reproduction.Frontiers in endocrinology · 2022Review
- Effects of growth hormone co-treatment on in vitro fertilization outcomes in women with expected normal ovarian responseTurkish journal of obstetrics and gynecology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGrowth hormone (GH) is used as an adjuvant therapy in in vitro fertilization and embryo transfer (IVF-ET) for poor ovarian responders, but findings for its effects on outcomes of IVF have been conflicting. The aim of the study was to compare IVF-ET outcomes among women with poor ovarian responders, and find which subgroup can benefit from the GH addition.
methodsWe searched the databases, using the terms "growth hormone," "GH," "IVF," "in vitro fertilization." Randomized controlled trials (RCT) were included if they assessed pregnancy rate, live birth rate, collected oocytes, fertilization rate, and implantation rate. Extracted the data from the corresponding articles, Mantel-Haenszel random-effects model, or fixed-effects model was used. Eleven studies were included.
resultsClinical pregnancy rate (RR 1.65, 95% CI 1.23-2.22), live birth rate (RR1.73, 1.25-2.40), collected oocytes number (SMD 1.09, 95% CI 0.54-1.64), MII oocytes number (SMD 1.48, 0.84-2.13), and E2 on human chorionic gonadotropin (HCG) day (SMD 1.03, 0.18-1.89) were significantly increased in the GH group. The cancelled cycles rate (RR 0.65, 0.45-0.94) and the dose of gonadotropin (Gn) (SMD -0.83, -1.47, -0.19) were significantly lower in patients who received GH. Subgroup analysis indicated that the GH addition with Gn significantly increased the clinical pregnancy rate (RR 1.76, 1.25-2.48) and the live birth rate (RR 1.91, 1.29-2.83).
conclusionThe GH addition can significantly improve the clinical pregnancy rate and live birth rate. Furthermore, the GH addition time and collocation of medications may affect the pregnancy outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.